Primary Analysis of Phase 2 Results for Cemiplimab in Patients (pts) With Locally Advanced Basal Cell Carcinoma (laBCC) Who Progress on or Are Intolerant to Hedgehog Inhibitors (HHIs). J of Skin 2021, 5 (1), s4. https://doi.org/10.25251/skin.5.supp.4.